サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791598

CRISPRとCas遺伝子の世界市場

CRISPR and Cas Genes

出版日
ページ情報
英文 174 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
CRISPRとCas遺伝子の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 174 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

CRISPRとCas遺伝子の世界市場は2030年までに132億米ドルに達する見込み

2024年に51億米ドルと推定されるCRISPRとCas遺伝子の世界市場は、分析期間2024-2030年にCAGR 17.4%で成長し、2030年には132億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるキット＆試薬は、CAGR 19.0％を記録し、分析期間終了までに42億米ドルに達すると予測されます。ライブラリ分野の成長率は、分析期間中CAGR 18.6%と推定されます。

米国市場は13億米ドル、中国はCAGR16.3％で成長すると予測

米国のCRISPRとCas遺伝子市場は、2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに20億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.2％と14.8％と予測されています。欧州では、ドイツがCAGR約12.6%で成長すると予測されています。

世界のCRISPRとCas遺伝子市場- 主要動向と促進要因のまとめ

なぜCRISPR技術はバイオテクノロジーに革命を起こすのか？遺伝子編集の台頭を探る

世界のCRISPRとCas遺伝子市場は、遺伝子工学、生物医学研究、農業バイオテクノロジーにおける画期的な進歩により、急激な成長を遂げています。CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）技術は、前例のない精度と効率で精密な遺伝子編集を可能にする、ゲームを変えるツールとして登場しました。遺伝性疾患、がん、希少疾患の治療のための遺伝子治療への注目の高まりが、CRISPRベースのアプリケーションへの投資を後押ししています。さらに、農業バイオテクノロジー企業は、CRISPRを作物改良、耐病性、食品生産効率向上のために活用しています。合成生物学分野の拡大と個別化医療の開発が市場需要をさらに強化しており、CRISPRは標的遺伝子改変において重要な役割を果たしています。

市場をリードするCRISPRアプリケーションは？主要セグメントの内訳

市場セグメンテーションは様々なアプリケーションにセグメント化され、それぞれが特定の科学や医療の進歩に対応しています。遺伝子治療は依然として最も有望なアプリケーションの一つであり、CRISPRは鎌状赤血球貧血や嚢胞性線維症などの遺伝性疾患の原因となる遺伝子変異を修正するために使用されています。農業バイオテクノロジーも重要な分野のひとつであり、CRISPRは干ばつ耐性、耐病性、栄養価の強化によって作物開発に革命をもたらしています。CRISPRに基づく診断の台頭も、特にCOVID-19を含む感染症の検出において牽引役となっています。さらに、創薬の分野では、遺伝子操作された細胞モデルを作成するCRISPRの能力の恩恵を受けており、医薬品の研究開発を改善しています。合成生物学や産業応用のためのCRISPRベースのバイオ製造ソリューションの開発は、市場機会をさらに多様化しています。

イノベーションはどのようにCRISPR市場を牽引しているのか？AI、自動化、倫理的配慮の役割

CRISPR市場は、AIを活用した遺伝子編集、遺伝子スクリーニングの自動化、ゲノム改変における倫理的進歩など、絶え間ないイノベーションによって急速に進化しています。AIを駆使したバイオインフォマティクス・ツールはCRISPRの効率を高め、研究者がオフターゲット効果を予測し、遺伝子編集の精度を最適化することを可能にしています。Cas12やCas13などの次世代Casタンパク質の開発により、CRISPRの汎用性が拡大し、RNAベースの改変や特異性の向上が可能になりました。さらに、ロボットラボシステムによるCRISPRワークフローの自動化は、研究の生産性を加速させ、手作業の介入を減らし、スループットを向上させています。遺伝子編集、特にヒト生殖細胞系列の改変をめぐる倫理的な調査は、責任ある研究実践を確保するための規制の枠組みや生命倫理に関する議論を促しています。DNA配列に変更を加えることなく遺伝子発現を改変するCRISPRベースのエピジェネティック編集の出現は、複雑な疾患の治療に新たな可能性をもたらしています。

何がCRISPR市場の成長を牽引しているのか？主な市場インフルエンサーを解説

CRISPR市場の成長を牽引しているのは、遺伝子研究への投資の増加、医療や農業への応用拡大、継続的な技術進歩です。プレシジョン・メディシンの台頭は、CRISPRベースの治療に対する需要を煽り、遺伝性疾患やがんに対する個別化治療ソリューションを提供しています。さらに、政府の資金援助や学術研究の取り組みにより、CRISPRベースの創薬や疾患モデリングのイノベーションが加速しています。気候変動に強い作物に対する農業部門のニーズの高まりは、CRISPRの採用をさらに後押しし、食糧安全保障の課題に対する持続可能な解決策を提供しています。バイオテクノロジー新興企業の拡大や製薬会社と研究機関の提携は、市場競争力を強化しています。しかし、倫理面や規制面への配慮は依然として重要な要素であり、CRISPRの商業化のペースに影響を及ぼしています。進行中の科学的ブレークスルーと進化する規制状況により、世界のCRISPRとCas遺伝子市場は、遺伝子工学と個別化ヘルスケアにおける新たな可能性を解き放ち、変革的な成長を示すことが期待されます。

セグメント

製品＆サービス（キット＆試薬、ライブラリー、デザインツール、抗体、細胞株工学、gRNAデザイン＆合成＆合成、スクリーニングサービス）、用途（バイオ医療用途、農業用途）、最終用途（バイオテクノロジー＆製薬企業最終用途、学術＆政府研究機関最終用途、受託研究機関最終用途、その他最終用途）

調査対象企業の例

  • Addgene
  • Agilent Technologies
  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • CRISPR Therapeutics
  • Editas Medicine
  • GenScript
  • Horizon Discovery（PerkinElmer）
  • Integrated DNA Technologies（IDT）
  • Intellia Therapeutics
  • Locus Biosciences
  • Mammoth Biosciences
  • Merck KGaA
  • New England Biolabs
  • Origene Technologies
  • Sangamo Therapeutics
  • Synthego Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30290

Global CRISPR and Cas Genes Market to Reach US$13.2 Billion by 2030

The global market for CRISPR and Cas Genes estimated at US$5.1 Billion in the year 2024, is expected to reach US$13.2 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 19.0% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Libraries segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 16.3% CAGR

The CRISPR and Cas Genes market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.2% and 14.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global CRISPR and Cas Genes Market - Key Trends & Drivers Summarized

Why Is CRISPR Technology Revolutionizing Biotechnology? Exploring the Rise of Gene Editing

The global CRISPR and Cas genes market has seen exponential growth, driven by groundbreaking advancements in genetic engineering, biomedical research, and agricultural biotechnology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a game-changing tool, enabling precise gene editing with unprecedented accuracy and efficiency. The increasing focus on gene therapy for treating genetic disorders, cancer, and rare diseases has propelled investment in CRISPR-based applications. Additionally, agricultural biotechnology firms are leveraging CRISPR for crop improvement, disease resistance, and enhanced food production efficiency. The expanding field of synthetic biology and the development of personalized medicine have further strengthened market demand, with CRISPR playing a crucial role in targeted genetic modifications.

Which CRISPR Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR and Cas genes market is segmented into various applications, each catering to specific scientific and medical advancements. Gene therapy remains one of the most promising applications, with CRISPR being used to correct genetic mutations responsible for inherited disorders such as sickle cell anemia and cystic fibrosis. Agricultural biotechnology is another key segment, where CRISPR is revolutionizing crop development by enhancing drought resistance, disease tolerance, and nutritional content. The rise of CRISPR-based diagnostics has also gained traction, particularly in detecting infectious diseases, including COVID-19. Additionally, the field of drug discovery is benefiting from CRISPR’s ability to create genetically engineered cell models, improving pharmaceutical research and development. The development of CRISPR-based biomanufacturing solutions for synthetic biology and industrial applications has further diversified market opportunities.

How Is Innovation Driving the CRISPR Market? The Role of AI, Automation & Ethical Considerations

The CRISPR market is evolving rapidly with continuous innovations in AI-powered gene editing, automation in genetic screening, and ethical advancements in genome modification. AI-driven bioinformatics tools have enhanced CRISPR efficiency, enabling researchers to predict off-target effects and optimize gene-editing accuracy. The development of next-generation Cas proteins, such as Cas12 and Cas13, has expanded CRISPR’s versatility, allowing for RNA-based modifications and improved specificity. Additionally, the automation of CRISPR workflows through robotic lab systems has accelerated research productivity, reducing manual intervention and increasing throughput. Ethical considerations surrounding gene editing, particularly in human germline modifications, have prompted regulatory frameworks and bioethical discussions to ensure responsible research practices. The emergence of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR Market? Key Market Influencers Explained

The growth in the CRISPR and Cas genes market is driven by increasing investment in genetic research, expanding applications in medicine and agriculture, and continuous technological advancements. The rise of precision medicine has fueled demand for CRISPR-based therapies, offering personalized treatment solutions for genetic disorders and cancer. Additionally, government funding and academic research initiatives have accelerated innovation in CRISPR-based drug discovery and disease modeling. The agricultural sector’s growing need for climate-resilient crops has further boosted CRISPR adoption, providing sustainable solutions for food security challenges. The expansion of biotech startups and partnerships between pharmaceutical companies and research institutions has strengthened market competitiveness. However, ethical and regulatory considerations remain a critical factor, influencing the pace of CRISPR commercialization. With ongoing scientific breakthroughs and evolving regulatory landscapes, the global CRISPR and Cas genes market is expected to witness transformative growth, unlocking new possibilities in genetic engineering and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the CRISPR and Cas Genes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis, Screening Services); Application (Biomedical Application, Agricultural Application); End-Use (Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Addgene
  • Agilent Technologies
  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • CRISPR Therapeutics
  • Editas Medicine
  • GenScript
  • Horizon Discovery (PerkinElmer)
  • Integrated DNA Technologies (IDT)
  • Intellia Therapeutics
  • Locus Biosciences
  • Mammoth Biosciences
  • Merck KGaA
  • New England Biolabs
  • Origene Technologies
  • Sangamo Therapeutics
  • Synthego Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • CRISPR and Cas Genes - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Investment in Gene Editing and Biotechnology Research Spurs Growth in CRISPR and Cas Gene Technologies
    • Surge in Precision Medicine Applications Strengthens the Business Case for CRISPR-Based Therapeutics
    • Rising Demand for Genomic Agriculture Drives Adoption of CRISPR and Cas Genes in Crop Improvement
    • Expansion of Clinical Trials and Gene Therapy Development Generates Accelerated Demand for CRISPR-Cas9 Solutions
    • Technological Advancements in CRISPR/Cas Precision and Efficiency Propel Market Growth in Therapeutic Applications
    • Regulatory Advancements and Easing of Gene Editing Guidelines Expands Market Opportunity for CRISPR-Based Products
    • Rising Focus on Hereditary Disease Treatment and Prevention Accelerates Market Adoption of CRISPR Gene Therapy Solutions
    • Increased Public Awareness of Gene Editing Capabilities and Ethics Throws the Spotlight on Transparent and Responsible CRISPR Applications
    • Growing Investment from Venture Capital and Pharma Companies Strengthens the Case for CRISPR as a Mainstream Technology
    • Expansion of Biopharmaceutical Companies Leveraging CRISPR for Drug Discovery and Development Drives Market Growth
    • Rising Global Demand for Sustainable Agricultural Practices Drives Adoption of CRISPR-Cas Genes in Food Production
    • The Need for Rapid and Cost-Effective Diagnostic Tools Accelerates Demand for CRISPR in Point-of-Care Diagnostics
    • Ongoing Advancements in CRISPR Delivery Systems Drive Adoption of CRISPR Technologies in Clinical and Agricultural Markets
    • Increasing Prevalence of Genetic Disorders and Chronic Diseases Propels the Need for CRISPR-Cas9 Solutions in Healthcare
    • Surge in Ethical and Regulatory Debates Over Germline Editing Impacts Market Expansion and Adoption in Certain Regions
    • Integration of CRISPR with Artificial Intelligence for Drug Development and Personalized Medicine Expands Addressable Market Opportunity
    • The Rise of Gene Drives for Environmental and Pest Control Applications Generates New Market Opportunities for CRISPR Technologies
    • Growing Focus on Environmental Sustainability Strengthens the Case for CRISPR in Bioremediation and Waste Treatment
    • Enhanced CRISPR-based Screening and Research Tools Drive Demand for Advanced Genetic Research Solutions
    • The Expansion of Genomic Data Infrastructure and Bioinformatics Strengthens Market Demand for CRISPR and Cas Integration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CRISPR and Cas Genes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Design Tool by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Design Tool by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cell Line Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cell Line Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for gRNA Design & Synthesis & Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for gRNA Design & Synthesis & Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Screening Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Screening Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biotechnology & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic & Government Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biomedical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Biomedical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Agricultural Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Agricultural Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • JAPAN
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • CHINA
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • EUROPE
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for CRISPR and Cas Genes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • FRANCE
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • GERMANY
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • CRISPR and Cas Genes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Product & Service - Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for CRISPR and Cas Genes by Product & Service - Percentage Breakdown of Value Sales for Kits & Reagents, Libraries, Design Tool, Antibodies, Cell Line Engineering, gRNA Design & Synthesis & Synthesis and Screening Services for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by End-Use - Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for CRISPR and Cas Genes by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies End-Use, Academic & Government Research Institutes End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for CRISPR and Cas Genes by Application - Biomedical Application and Agricultural Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for CRISPR and Cas Genes by Application - Percentage Breakdown of Value Sales for Biomedical Application and Agricultural Application for the Years 2025 & 2030

IV. COMPETITION